The global most powerful information hub of high performance & advanced materials, innovative technologies

to market your brand and access to the global demand and supply markets

Three-year clinical follow-up data of China-produced absorbable stents show that the safety is far better than similar international stents Hay:P02BJLP

On February 26, 2021, China`s leading cardiovascular interventional medical device technology company, BJLP Medical Device Technology Group, issued an announcement that the bioabsorbable stent developed by the company is the first bio-absorbable stent product registered for sale in China. Three-year clinical follow-up data show that the long-term safety is far better than similar international stents;

The fully degradable occluder is the first clinically registered biodegradable occluder product in China, and is the only biodegradable occluder product in the world that has completed clinical implantation and is undergoing registration approval; the biodegradable PFO occluder has also begun clinical trials Implanting. In terms of international innovation and R&D, there are also a new generation of degradable coronary stents, biodegradable peripheral stents, biodegradable biliary stents, biodegradable left atrial appendage occluders, biodegradable atrial shunts, and biodegradable biodegradable coronary stents that are currently under development. Open and endoscope stapler for implantation of nails. With the increasing demand for life-long benefits and quality improvement of surgical "intervention without implantation" innovative devices, "intervention without implantation" has become a major trend in the development of the global medical industry, and this development trend will be sufficient Extending to the peripheral and neuro-intervention fields demanded by the larger market, the company will benefit from the clinical promotion and application of international innovative device products for a long time.

About BJLP Medical Device Technology Group

BJLP Medical Device Technology Group is one of China's leading enterprises in the R&D and manufacturing of cardiovascular interventional medical devices. It is the only national heart disease implant intervention diagnosis and treatment device and equipment engineering technology research center awarded by the Ministry of Science and Technology of China. It was the first batch of listed companies in 2009 One is one of the few companies that can form strong competition with foreign products in the field of high-end medical devices in China.

For more than 30 years, the company has always focused on serving patients with cardiovascular diseases, insisted on R&D and innovation, continued to grow and make breakthroughs in the fields of cardiovascular stents, cardiac pacemakers, cardiovascular drugs and medical artificial intelligence, and undertook a number of major national scientific research projects. Including the high-tech industrialization demonstration project of the National Development and Reform Commission, the 863 plan development project of the Ministry of Science and Technology, and the science and technology support plan project. At present, the company has developed into a leading domestic high-end medical product industry group of cardiovascular disease implant intervention diagnosis and treatment equipment and equipment, and its business covers four major sectors: medical equipment, pharmaceutical products, medical services and new medical formats.

The company adheres to the gradient development principle of "pre-research generation, registration generation and production and sales generation". Based on coronary drug stents, the company has entered the era of bio-absorbable medical devices and artificial AI intelligent medical devices. The company has international second-generation bioabsorbable stents, a new generation of intravascular drug (paclitaxel) eluting balloon catheters and other blockbuster products. The internationally leading artificial intelligence AI-ECG ECG analysis software system product has been approved by the US FDA and the European Union. CE certification and NMPA registration approval, with multiple technical characteristics of coronary drug stents, balloons, pacemakers, occluders, heart valves, angiography machines, IVD equipment and diagnostic reagents, surgical instruments, artificial intelligence ECG Equipment and household smart medical equipment, etc.

Please check the message before sending